Author/Authors :
Raisi، Firoozeh نويسنده Department of Psychiatry, Tehran University of Medical Science, Tehran, Iran. Raisi, Firoozeh , Zahiroddin، Alireza نويسنده Behavioral Science Research Center, Shahid Beheshti
University of Medical Sciences, Tehran, IR Iran , , Akhondzadeh، Shahin نويسنده , , Hashemian، Farshad نويسنده School of Pharmacy, Pharmaceutical Sciences Branch, Azad University (IAU), Tehran, Iran Hashemian, Farshad , Ghaeli، Padideh نويسنده PharmD, Psychiatric Research Center, Roozbeh Psychiatric Hospital, TUMS, Tehran , , Salmasi، Fiona Baroyant نويسنده School of Pharmacy, Pharmaceutical Sciences Branch, Azad University (IAU), Tehran, Iran Salmasi, Fiona Baroyant , Jazayeri، Maryam نويسنده , , Golchin، Kazem نويسنده Psychiatry and Psychology Research Center, Roozbeh Hospital Tehran University of Medical Sciences, Tehran, Iran Golchin, Kazem , Bajoghli، Hafez نويسنده Psychiatry & Psychology Research Center,Tehran University of Medcal Sciences
Department of Psychiatry, Tehran University of Medcal Sciences Bajoghli, Hafez , Afghah، Susan نويسنده University of Social Welfare and Rehabilitation, Tehran, Iran ,
Abstract :
Objective: To study the effects of a high dose alpha-tocopherol on serum total cholesterol (TC), triglyceride (TG), and the high density lipoprotein (HDL) levels of patients with schizophrenia receiving olanzapine.
Method: Thirty six adults diagnosed with schizophrenia based on DSM-IV who were taking olanzapine for a minimum of thirty days entered this eight-week, double blind, placebo-controlled study. Patients were randomized to receive alpha-tocopherol 400IU or placebo capsules twice a day for 2 weeks, then three times a day for 6 more weeks. Fasting total cholesterol (TC), triglyceride(TG),and HDL levels were measured at the baseline and weeks 4 and 8.
Results: TC, TG and HDL levels did not change significantly during this study. There were no significant differences in TC, TG and HDL levels between the two groups at the baseline and weeks 4 and 8.
Conclusion: High-dose vitamin may not improve triglyceride and cholesterol levels in patients who are already on olanzapine. Further studies with greater number of patients and for a longer duration are needed.
